Biosimilars approved in Europe

Biosimilars/General | Posted 08/07/2011 2 Post your comment

Last update: 28 January 2025

In the European Union (EU), a legal framework for approving biosimilars was established in 2003. This framework means that biosimilars can only be approved centrally via the European Medicines Agency (EMA) and not nationally.

EMA first developed guidelines for the approval of biosimilars via an abbreviated registration process during 2005 to 2006, and since then EMA has developed many general and specific guidelines for biosimilars [1].

Omnitrope (somatropin) was the first product approved in the EU as a biosimilar in 2006 [2]. To date, EMA has recommended the approval of 126 biosimilars within the product classes of: 1) human growth hormone; 2) granulocyte colony-stimulating factor; 3) erythropoiesis stimulating agent; 4) insulin; 5) follicle-stimulating hormone (FSH); 6) parathyroid hormone; 7) tumour necrosis factor (TNF)-inhibitor; 8) vascular endothelial growth factor (VEGF) inhibitor, and 9) monoclonal antibody for use in the EU, see Table 1.

On 21 March 2024, Sandoz received positive opinion from EMA’s Committee for Medicinal Products for Human Use (CHMP) for its biosimilar denosumab under two brand names – Jubbonti and Wyost.

On 17 October 2024, Accord received a positive opinion from EMA’s CHMP for its biosimilar ustekinumab under two brand names – Absimky/Imuldosa (DMB-3115) [3].

On 19 March 2024, Dr Reddy’s Laboratories announced that it would be launching Versavo, a bevacizumab biosimilar, in the UK [4]. However, Versavo has not yet been submitted to the EMA for approval. Also in March 2024, Formycon’s biosimilar ranibizumab, Ravegza (FYB201), received marketing authorization from the Saudi Food & Drug Authority. This product is approved in Europe under the brand name Ranivisio [5].

Table 1: EMA approved biosimilars*

Product name	Active substance	Therapeutic area	Authorization date	Manufacturer/ Company name
Abasaglar (previously Abasria)	insulin glargine	Diabetes mellitus	9 Sep 2014	Eli Lilly/Boehringer Ingelheim
Abevmy	bevacizumab	Breast cancer Carcinoma of the cervix Colon cancer Fallopian tube cancer Non-small-cell lung carcinoma Ovarian cancer Peritoneal cancer Renal cell cancer	21 Apr 2021	Mylan (now Viatris)
Abseamed	epoetin alfa	Anaemia Cancer Chronic kidney failure	27 Aug 2007	Medice Arzneimittel Pütter
Absimky	ustekinumab	Crohn’s disease Paediatric psoriatic arthritis Plaque psoriasis Psoriatic arthritis	CHMP positive opinion 17 Oct 2024	Accord Healthcare
Accofil	filgrastim	Neutropenia	17 Sep 2014	Accord Healthcare
Afqlir	aflibercept	Diabetic macular oedema (DME) Macular oedema following retinal vein occlusion (branch RVO or central RVO) Myopic choroidal neovascularisation (myopic CNV) Neovascular (wet) age-related macular degeneration (AMD)	CHMP positive opinion 19 Sep 2024	Sandoz
Ahzantive/Baiama (FYB203)	aflibercept	Diabetic macular oedema (DME) Myopic choroidal neovascularisation (myopic CNV) Neovascular (wet) age-related macular degeneration (AMD) Visual impairment due to macular oedema secondary to retinal vein occlusion	CHMP positive opinion 14 Nov 2024	Formycon AG
Alymsys	bevacizumab	Breast cancer Carcinoma of the cervix Colon cancer Fallopian tube cancer Non-small-cell lung carcinoma Ovarian cancer Peritoneal cancer Renal cell cancer	26 Mar 2021	mAbxience Research
Amgevita	adalimumab	Ankylosing spondylitis Crohn’s disease Juvenile rheumatoid arthritis Psoriasis Psoriatic arthritis Rheumatoid arthritis Ulcerative colitis	21 Mar 2017	Amgen
Amsparity	adalimumab	Ankylosing spondylitis Hidradenitis Suppurativa Crohn’s disease Juvenile rheumatoid arthritis Psoriasis Psoriatic arthritis Rheumatoid arthritis Ulcerative colitis Uvetis	13 Feb 2020	Pfizer
Aybintio	bevacizumab	Breast neoplasms Colorectal neoplasms Fallopian tube neoplasms Non-small-cell lung carcinoma Ovarian neoplasms Peritoneal neoplasms Renal cell carcinoma Uterine cervical neoplasms	19 Aug 2020	Samsung Bioepis
Avtozma	tocilizumab	COVID-19 Cytokine release syndrome (CRS) Giant cell arteritis (GCA) Polyarticular juvenile idiopathic arthritis (pJIA) Rheumatoid arthritis Systemic juvenile idiopathic arthritis (sJIA)	CHMP positive opinion 12 Dec 2024	Celltrion
Avzivi	bevacizumab	Carcinoma, non-small-cell lung Carcinoma, renal cell Colorectal neoplasms Fallopian tube neoplasms Ovarian neoplasms Peritoneal neoplasms Uterine cervical neoplasms	26 July 2024	Bio-Thera Solutions, marketed by Sandoz
Bekemv	eculizumab	Atypical haemolytic uraemic syndrome (aHUS) Paroxysmal nocturnal haemoglobinuria (PNH)	24 Feb 2023	Amgen
Bemfola	follitropin alfa	Anovulation (IVF)	26 Mar 2014	Finox Biotech
Benepali	etanercept	Axial spondyloarthritis Psoriatic arthritis Plaque psoriasis Rheumatoid arthritis	13 Jan 2016	Samsung Bioepis
Binocrit	epoetin alfa	Anaemia Chronic kidney failure	28 Aug 2007	Sandoz
Blitzima	rituximab	Non-Hodgkin lymphoma Chronic B-cell lymphocytic leukaemia	13 Jul 2017	Celltrion
Byooviz	ranibizumab	Degenerative myopia Diabetic retinopathy Macular edema Wet macular degeneration	18 Aug 2021	Samsung Bioepis
Cegfila (previously Pegfilgrastim Mundipharma)	pegfilgrastim	Neutropenia	19 Dec 2019	Mundipharma Biologics
Eksunbi	ustekinumab	Crohn’s disease Paediatric plaque psoriasis Plaque psoriasis Psoriatic arthritis Ulcerative colitis	12 Sep 2024	Samsung Bioepis NL BV
Enoxaparin BECAT	enoxaparin sodium	Venous thromboembolism	24 Mar 2017	Laboratorios ROVI
Epoetin alfa Hexal	epoetin alfa	Anaemia Cancer Chronic kidney failure	27 Aug 2007	Hexal
Epysqli	eculizumab	Atypical Hemolytic Uremic Syndrome (aHUS) Paroxysmal nocturnal hemoglobinuria: adult and children	26 May 2023 22 Mar 2024 (for aHUS)	Samsung Bioepis
Erelzi	etanercept	Ankylosing spondylitis Juvenile rheumatoid arthritis Psoriasis Psoriatic arthritis Rheumatoid arthritis	23 Jun 2017	Sandoz
Eydenzelt (CT-P42)	aflibercept	Diabetic macular oedema (DME) Myopic choroidal neovascularisation (myopic CNV) Neovascular (wet) age-related macular degeneration (AMD) Visual impairment due to macular oedema secondary to retinal vein occlusion	CHMP positive opinion 12 Dec 2024	Celltrion
Filgrastim Hexal	filgrastim	Cancer Haematopoietic stem cell transplantation Neutropenia	6 Feb 2009	Hexal
Flixabi	infliximab	Ankylosing spondylitis Crohn’s disease Psoriatic arthritis Psoriasis Rheumatoid arthritis Ulcerative colitis	26 May 2016	Samsung Bioepis
Fulphila	pegfilgrastim	Neutropenia	20 Nov 2018	Mylan (now Viatris)
Fymskina	ustekinumab	Crohn’s disease Paediatric plaque psoriasis Plaque psoriasis Psoriatic arthritis Ulcerative colitis	25 Sep 2024	Formycon AG
Grastofil	filgrastim	Neutropenia	17 Oct 2013	Apotex
Grasustek	pegfilgrastim	Neutropenia	20 Jun 2019	Juta Pharma (USV)
Hefiya	adalimumab	Ankylosing spondylitis Hidradenitis suppurativa Juvenile rheumatoid arthritis Psoriasis Uveitis	26 Jul 2018	Sandoz
Herzuma	trastuzumab	Early breast cancer Metastatic breast cancer Metastatic gastric cancer	8 Feb 2018	Celltrion Healthcare
Herwenda	trastuzumab	Early breast cancer Metastatic breast cancer Metastatic gastric cancer	15 Nov 2023	Sandoz GmbH
Hukyndra	adalimumab	Ankylosing spondylitis Crohn’s Disease Hidradenitis suppurativa Psoriasis Psoriatic arthritis Rheumatoid arthritis Ulcerative Colitis Uveitis	15 Nov 2021	Alvotech/Stada Artnimettel
Hulio	adalimumab	Ankylosing spondylitis Crohn’s Disease Hidradenitis suppurativa Psoriasis Psoriatic arthritis Rheumatoid arthritis Ulcerative Colitis Uveitis	17 Sep 2018	Mylan/Fujifilm Kyowa Kirin Biologics
Hyrimoz	adalimumab	Ankylosing spondylitis Crohn’s Disease Hidradenitis suppurativa Juvenile rheumatoid arthritis Papulosquamous skin disease Psoriatic arthritis Rheumatoid arthritis Ulcerative Colitis Uveitis	26 Jul 2018	Sandoz
Idacio	adalimumab	Ankylosing spondylitis Arthritis Crohn’s Disease Hidradenitis suppurativa Psoriatic arthritis Psoriasis Rheumatoid arthritis Ulcerative colitis Uveitis	2 Apr 2019	Fresenius Kabi
Imraldi	adalimumab	Ankylosing spondylitis Arthritis Crohn’s Disease Hidradenitis suppurativa Psoriatic arthritis Psoriasis Rheumatoid arthritis Ulcerative colitis Uveitis	24 Aug 2017	Samsung Bioepis
Imuldosa	ustekinumab	Crohn’s disease paediatric psoriatic arthritis plaque psoriasis psoriatic arthritis ulcerative colitis	CHMP positive opinion 17 Oct 2024	Accord Healthcare
Inflectra	infliximab	Ankylosing spondylitis Crohn’s disease Psoriatic arthritis Psoriasis Rheumatoid arthritis Ulcerative colitis	10 Sep 2013	Hospira (Pfizer)
Inhixa	enoxaparin sodium	Venous thromboembolism	15 Sep 2016	Techdow Europe
Insulin aspart Sanofi	insulin aspart	Diabetes mellitus	25 Jun 2020	Sanofi-Aventis
Insulin lispro Sanofi	insulin lispro	Diabetes mellitus	18 Jul 2017	Sanofi-Aventis
Ituxredi	rituximab	Chronic lymphocytic leukaemia Granulomatosis with polyangiitis and microscopic polyangiitis Non-Hodgkin’s lymphoma Pemphigus vulgar Rheumatoid arthritis	CHMP positive opinion 25 Jul 2024	Reddy Holding
Jubbonti	denosumab	Bone resorption Osteoporosis Postmenopausal osteoporosis	16 May 2024	Sandoz GmbH
Kanjinti	trastuzumab	Early breast cancer Metastatic breast cancer Metastatic gastric cancer	16 May 2018	Amgen/Allergan
Kirsty (previously Kixelle)	insulin aspart	Diabetes mellitus	5 February 2021	Biocon/Viatris (formerly Mylan)
Libmyris	adalimumab	Ankylosing spondylitis Crohn’s Disease Hidradenitis suppurativa Psoriasis Psoriatic arthritis Rheumatoid arthritis Ulcerative Colitis Uveitis	12 Nov 2021	Alvotech/Stada Artnimettel
Livogiva	teriparatide	Osteoporosis	27 Aug 2020	Theramex Ireland
Movymia	teriparatide	Osteoporosis	11 Jan 2017	Stada Arzneimittel
Mvasi	bevacizumab	Breast neoplasms Fallopian tube neoplasms Non-small-cell lung carcinoma Ovarian neoplasms Peritoneal neoplasms Renal cell carcinoma	15 Jan 2018	Amgen
Nepexto	etanercept	Ankylosing spondylitis Juvenile rheumatoid arthritis Psoriasis Psoriatic arthritis Rheumatoid arthritis Spondylarthropathies	25 May 2020	Mylan (now Viatris)
Nivestim	filgrastim	Cancer Haematopoietic stem cell transplantation Neutropenia	7 Jun 2010	Hospira (Pfizer)
Nyvepria	pegfilgrastim	Neutropenia	18 Nov 2020	Pfizer
Obodence	denosumab	Bone resorption Osteoporosis Postmenopausal osteoporosis	CHMP positive opinion 14 Nov 2024	Samsung Bioepis
Ogivri	trastuzumab	Early breast cancer Metastatic breast cancer Metastatic gastric cancer	12 Dec 2018	Biocon/Mylan
Omlyclo	omalizumab	Asthma Urticaria	23 May 2024	Celltrion Healthcare
Omnitrope	somatropin	Pituitary dwarfism Prader-Willi syndrome Turner syndrome	12 Apr 2006	Sandoz
Onbevzi	bevacizumab	Breast neoplasms Colorectal neoplasms Fallopian tube neoplasms Non-small-cell lung carcinoma Ovarian neoplasms Peritoneal neoplasms Renal cell carcinoma Uterine Cervical Neoplasms	11 Jan 2021	Samsung Bioepis
Ontruzant	trastuzumab	Early breast cancer Metastatic breast cancer Metastatic gastric cancer	15 Nov 2017	Samsung Bioepis
Opuviz	aflibercept	Diabetic macular oedema (DME) Macular oedema following retinal vein occlusion (branch RVO or central RVO) Myopic choroidal neovascularisation (myopic CNV) Neovascular (wet) age-related macular degeneration (AMD)	CHMP positive opinion 19 Sep 2024	Samsung Bioepis
Osenvelt	denosumab	Giant cell tumor of bone Neoplasms, Bone tissue	CHMP positive opinion 12 Dec 2024	Celltrion
Otulfi	ustekinumab	Crohn’s disease Paediatric plaque psoriasis Plaque psoriasis Psoriatic arthritis Ulcerative colitis	25 Sep 2024	Fresenius Kabi
Oyavas	bevacizumab	Breast cancer Carcinoma of the cervix Colon cancer Fallopian tube cancer Non-small-cell lung carcinoma Ovarian cancer Peritoneal cancer Renal cell cancer	26 Mar 2021	Stada Arzneimittel
Ovaleap	follitropin alfa	Anovulation (IVF)	27 Sep 2013	Teva Pharma
Pelgraz	pegfilgrastim	Neutropenia	21 Sep 2018	Accord Healthcare
Pelmeg	pegfilgrastim	Neutropenia	20 Nov 2018	Cinfa Biotech/Mundipharma
Pyzchiva	ustekinumab	Crohn’s disease Paediatric plaque psoriasis Psoriatic arthritis Ulcerative colitis	22 Apr 2024	Samsung Bioepis
Ratiograstim	filgrastim	Cancer Haematopoietic stem cell transplantation Neutropenia	15 Sep 2008	Ratiopharm
Remsima	infliximab	Ankylosing spondylitis Crohn’s disease Psoriatic arthritis Psoriasis Rheumatoid arthritis Ulcerative colitis	10 Sep 2013	Celltrion
Ranibizumab Midas	ranibizumab	Neovascular (wet) age-related macular degeneration (AMD) Visual impairment due to diabetic macular oedema (DME) Proliferative diabetic retinopathy (PDR) Visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) Visual impairment due to choroidal neovascularisation (CNV)	CHMP positive opinion 25 July 2024	Midas Pharma GmbH
Ranivisio	ranibizumab	Diabetes complications Diabetic retinopathy Macular edema Wet macular degeneration	25 Aug 2022	Bioeq/Teva Pharma
Retacrit	epoetin zeta	Anaemia Autologous blood transfusion Cancer Chronic kidney failure	18 Dec 2007	Hospira (Pfizer)
Rimmyrah	ranibizumab	Neovascular (wet) age-related macular degeneration (AMD) Visual impairment due to diabetic macular oedema (DME) Proliferative diabetic retinopathy (PDR) Visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) Visual impairment due to choroidal neovascularisation (CNV)	5 Jan 2024	Qilu Pharma
Rixathon	rituximab	Chronic B-cell ly+C85mphocytic leukaemia Microscopic polyangiitis Non-Hodgkin Lymphoma Rheumatoid arthritis Wegener granulomatosis	15 Jun 2017	Sandoz
Riximyo	rituximab	Chronic B-cell lymphocytic leukaemia Microscopic polyangiitis Non-Hodgkin Lymphoma Rheumatoid arthritis Wegener granulomatosis	15 Jun 2017	Sandoz
Ruxience	rituximab	Chronic lymphocytic leukaemia Granulomatosis with polyangiitis Microscopic polyangiitis Non-Hodgkin Lymphoma Rheumatoid arthritis Pemphigus vulgaris	1 Apr 2020	Pfizer
Semglee	insulin glargine	Diabetes mellitus	28 Mar 2018	Biocon/Viatris (formerly Mylan)
Silapo	epoetin zeta	Anaemia Autologous blood transfusion Cancer Chronic kidney failure	18 Dec 2007	Stada Arzneimittel
Sondelbay	teriparatide	Osteoporosis	24 Mar 2022	Accord Healthcare
Steqeyma	ustekinumab	Crohn’s disease Paediatric plaque psoriasis Plaque psoriasis Psoriatic arthritis	22 Aug 2024	Celltrion
Stimufend	pegfilgrastim	Neutropenia	24 Mar 2022	Fresenius Kabi
Stoboclo	denosumab	Bone resorption Osteoporosis Postmenopausal osteoporosis	CHMP positive opinion 12 Dec 2024
Terrosa	teriparatide	Osteoporosis	4 Jan 2017	Gedeon Richter
Tevagrastim	filgrastim	Cancer Haematopoietic stem cell transplantation Neutropenia	15 Sep 2008	Teva Generics
Tofidence	tocilizumab	Polyarticular juvenile idiopathic arthritis Rheumatoid arthritis Systemic juvenile idiopathic arthritis	20 Jun 2024	Biogen
Trazimera	trastuzumab	Stomach Neoplasms Breast Neoplasms	26 Jul 2018	Pfizer
Truvelog Mix 30	insulin aspart	Diabetes mellitus	Apr 2022	Sanofi-Aventis
Truxima	rituximab	Chronic lymphocytic leukaemia Granulomatosis with polyangiitis Microscopic polyangiitis Non-Hodgkin’s lymphoma Rheumatoid arthritis	17 Feb 2017	Celltrion Healthcare
Tuznue	trastuzumab	Breast cancer Metastatic gastric cancer	CHMP positive opinion 25 July 2024	Prestige Biopharma Belgium BVBA
Tyenne	tocilizumab	Active systemic juvenile idiopathic arthritis Chimeric antigen receptor T cell-induced cytokine release syndrome COVID-19 Giant cell arteritis Juvenile idiopathic polyarthritis	15 Sep 2023	Fresenius Kabi Deutschland GmbH
Tyruko	natalizumab	Multiple sclerosis Relapsing-remitting multiple sclerosis	26 Sep 2023	Sandoz GmbH
Uzpruvo	ustekinumab	Plaque psoriasis Paediatric plaque psoriasis Psoriatic arthritis (PsA) Crohn’s Disease	5 Jan 2024	Alvotech/Stada Arzneimittel AG
Vegzelma	bevacizumab	Breast neoplasms Colorectal neoplasms Non-small-cell lung carcinoma Ovarian neoplasms Renal cell carcinoma	17 Aug 2022	Celltrion Healthcare
Wezenla	ustekinumab	Crohn’s disease Plaque psoriasis, including paediatric plaque psoriasis Psoriatic arthritis	20 Jun 2024	Amgen
Wyost	denosumab	Giant cell tumor of bone Neoplasms, Bone tissue	16 May 2024	Sandoz GmbH
Ximluci	ranibizumab	Diabetes complications Diabetic retinopathy Macular edema Wet macular degeneration	9 Nov 2022	Stada Arzneimittel/Xbrane Biopharma
Xbryk	denosumab	Giant cell tumor of bone Neoplasms, Bone tissue	CHMP positive opinion 14 Nov 2024	Samsung Bioepis
Yesafili	aflibercept	Degenerative diabetes complications Diabetic retinopathy myopia Macular oedema Retinal vein occlusion	15 Sep 2023	Biocon/Viatris (formerly Mylan)
Yesintek	ustekinumab	Crohn’s disease Paediatric plaque psoriasis Plaque psoriasis Psoriatic arthritis (PsA)	CHMP positive opinion 12 Dec 2024	Biocon
Yuflyma	adalimumab	Axial spondyoarthritis Crohn’s Disease Juvenile idiopathic arthritis Hidradenitis suppurativa Psoriatic arthritis Psoriasis Rheumatoid arthritis Ulcerative colitis Uveitis	11 Feb 2021	Celltrion Healthcare
Zarzio	filgrastim	Cancer Haematopoietic stem cell transplantation Neutropenia	6 Feb 2009	Sandoz
Zefylti	filgrastim	Cancer Haematopoietic stem cell transplantation Neutropenia	CHMP positive opinion 12 Dec 2024	CuraTeQ Biologics (Aurobindo)
Zercepac	trastuzumab	Stomach Neoplasms Breast Neoplasms	27 Jul 2020	Accord Healthcare
Zessly	infliximab	Ankylosing spondylitis Crohn’s disease Psoriatic arthritis psoriasis Rheumatoid arthritis Ulcerative colitis	18 May 2018	Sandoz
Ziextenzo	pegfilgrastim	Neutropenia	22 Nov 2018	Sandoz
Zirabev	bevacizumab	Breast neoplasms Colorectal neoplasms Non-small-cell lung carcinoma Renal cell carcinoma Uterine cervical neoplasms	14 Feb 2019	Pfizer

*Data updated on 28 January 2025
CHMP: Committee for Medicinal Products for Human Use; IVF: in vitro fertilization.
Source: EMA

Seventeen biosimilar approvals have been withdrawn after approval, see Table 2:
• four for adalimumab biosimilars: Boehringer Ingelheim’s Cyltezo in January 2019, Amgen’s Solymbic in March 2019, Fresenius Kabi’s Kromeya in December 2019 and Sandoz’s Halimatoz in January 2021
• two for bevacizumab biosimilars: Equidacent from Centus Biotherapeutics in November 2021 and Mylan’s (now Viatris) Lextemy in December 2021
• one for an enoxaparin sodium biosimilar: Pharmathen’s Thorinane in October 2019
• two for filgrastim biosimilars: Filgrastim ratiopharm in April 2011 and CT Arzneimittel’s Biograstim in December 2016
• one for an human insulin biosimilar: Biocon’s Inpremzia in April 2023
• one for an insulin glargine biosimilar: Merck’s Lusduna in October 2018
• one for a pegfilgrastim biosimilar: ERA Consulting’s (Coherus Biosciences) Udenyca in February 2021
• two for rituximab biosimilars: Celltrion’s Rituzena in April 2019 and Celltrion’s Ritemvia in August 2021
• two for somatropin biosimilars: Biopartner’s Valtropin in May 2012 and Somatropin Biopartners in November 2017
• one for a teriparatide biosimilar: Qutavina from EuroGenerics Holdings in January 2018

Table 2: EMA refused/withdrawn biosimilars*

Product name	Active substance	Therapeutic area	Authorization date	Manufacturer/ Company name
Alpheon	interferon alfa-2a	Chronic hepatitis C	Refused 5 Sep 2006	BioPartners
Biograstim	filgrastim	Cancer Haematopoietic stem cell transplantation Neutropenia	15 Sep 2008 Withdrawn on 22 Dec 2016	CT Arzneimittel
Cavoley	pegfilgrastim	Neutropenia	Withdrawn on 20 Dec 2018	Stada Artnimettel
Cyltezo	adalimumab	Crohn’s disease Hidradenitis suppurativa Juvenile idiopathic arthritis Psoriasis Psoriatic arthritis Rheumatoid arthritis Ulcerative colitis Uveitis	10 Nov 2017 Withdrawn on 15 Jan 2019	Boehringer Ingelheim
Efgratin	pegfilgrastim	Neutropenia	Withdrawn on 16 Nov 2016	Gedeon Richter
Epostim	epoetin alfa	Anaemia	Withdrawn 15 Mar 2011	Reliance GeneMedix
Equidacent	bevacizumab	Breast neoplasms Colorectal neoplasms Non-small-cell lung carcinoma Ovarian neoplasms Renal cell carcinoma	24 Sep 2020 Withdrawn on 23 Nov 2021	Centus Biotherapeutics
Filgrastim ratiopharm	filgrastim	Cancer Haematopoietic stem cell transplantation Neutropenia	15 Sep 2008 Withdrawn on 20 Apr 2011	Ratiopharm
Halimatoz	adalimumab	Ankylosing spondylitis Hidradenitis suppurativa Juvenile rheumatoid arthritis Psoriatic arthritis Psoriasis Rheumatoid arthritis Uveitis	26 Jul 2018 Withdrawn on 29 Jan 2021	Sandoz
Inpremzia	insulin human	Diabetes	25 Apr 2022 Withdrawn on 20 Apr 2023
Kromeya	adalimumab	Ankylosing spondylitis Arthritis Crohn’s Disease Hidradenitis suppurativa Psoriatic arthritis Psoriasis Rheumatoid arthritis Ulcerative colitis Uveitis	2 Apr 2019 Withdrawn on 17 Dec 2019	Fresenius Kabi
Lextemy	bevacizumab	Breast cancer Carcinoma of the cervix Colon cancer Fallopian tube cancer Non-small-cell lung carcinoma Ovarian cancer Peritoneal cancer Renal cell cancer	CHMP positive opinion 25 Feb 2021 Withdrawn on 14 Dec 2021	Mylan (now Viatris)
Lusduna	insulin glargine	Diabetes	3 Jan 2017 Withdrawn on 29 Oct 2018	Merck (MSD)
Qutavina	teriparatide	Osteoporosis	27 Aug 2020 Withdrawn on 18 Jan 2021	EuroGenerics Holdings
Ritemvia	rituximab	Wegener granulomatosis Microscopic polyangiitis Non-Hodgkin Lymphoma	13 Jul 2017 Withdrawn on 16 Aug 2021	Celltrion
Rituximab Mabion	rituximab	Chronic lymphocytic leukaemia Granulomatosis with polyangiitis Microscopic polyangiitis Non-Hodgkin Lymphoma	Withdrawn on 16 Mar 2020	Mabion
Rituzena (previously Tuxella)	rituximab	Wegener granulomatosis Microscopic polyangiitis Non-Hodgkin Lymphoma Chronic B-cell lymphocytic leukaemia	13 Jul 2017 Withdrawn on 10 Apr 2019	Celltrion
Solumarv	insulin human	Diabetes	Refused 11 Feb 2016	Marvel Lifesciences
Solymbic	adalimumab	Ankylosing spondylitis Crohn’s disease Hidradenitis suppurativa Psoriasis Psoriatic arthritis Rheumatoid arthritis Ulcerative colitis	22 Mar 2017 Withdrawn on 5 Mar 2019	Amgen
Somatropin Biopartners	somatropin	Pituitary dwarfism Turner syndrome	9 Sep 2013 Withdrawn on 9 Nov 2017	BioPartners
Thorinane	enoxaparin sodium	Venous thromboembolism	14 Sep 2016 Withdrawn on 24 Oct 2019	Pharmathen
Udenyca	pegfilgrastim	Neutropenia	21 Sep 2018 Withdrawn on 15 Feb 2021	ERA Consulting (Coherus Biosciences)
Valtropin	somatropin	Pituitary dwarfism Turner syndrome	24 Apr 2006 Withdrawn on 10 May 2012	BioPartners

*Data updated on 16 July 2024
Source: EMA

Four biosimilar were withdrawn before approval: Reliance GeneMedix’s epoetin alfa biosimilar, Epostim; Mabion’s rituximab biosimilar, and the pegfilgrastim biosimilars of Stada’s Cavoley and Gedeon Richter’s Efgratin, see Table 2.

Two biosimilar applications were refused by the agency: an interferon alfa-2a biosimilar, Alpheon, from Biopartners; and a human insulin biosimilar, Solumarv, from Marvel Lifesciences, see Table 2.

By the end of December 2024, a total of 17 biosimilars have been withdrawn after approval. Additionally, four biosimilars were withdrawn before gaining approval, and two were refused approval. These biosimilars fall into the following therapeutic classes: 1) human growth hormone; 2) granulocyte colony-stimulating factor; 3) erythropoiesis stimulating agent; 4) insulin; 5) parathyroid hormone; and 6) monoclonal antibody.

This leaves a total of 109 biosimilars approved for use in Europe.

The positive opinion reached by the EMA’s CHMP on 26 July 2014 for the insulin glargine biosimilar Abasaglar (previously Abasria) came as a relief to diabetes sufferers in Europe, after the disappointing withdrawal of the applications for three biosimilar insulin products by Marvel LifeSciences in November 2012 [5]. The positive opinion reached by the EMA’s CHMP on 27 June 2013 for the infliximab biosimilars Inflectra and Remsima was a landmark decision, proving that the biosimilar concept can be successfully applied to such complex molecules as monoclonal antibodies.

Related articles
Remsima approved in Colombia

EMA approves first monoclonal antibody biosimilar

References
1. GaBI Online - Generics and Biosimilars Initiative. EU guidelines for biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Jul 4]. Available from: www.gabionline.net/Guidelines/EU-guidelines-for-biosimilars
2. GaBI Online - Generics and Biosimilars Initiative. Biosimilars use in Europe [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Jul 4]. Available from: www.gabionline.net/Reports/Biosimilars-use-in-Europe
3. GaBI Online - Generics and Biosimilars Initiative. EMA recommends approval for ustekinumab biosimilar Absimky and Imuldosa [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2025 Jan 28]. Available from: www.gabionline.net/biosimilars/news/ema-recommends-approval-for-ustekinumab-biosimilar-absimky-and-imuldosa
4. GaBI Online - Generics and Biosimilars Initiative. Dr Reddy's launches bevacizumab biosimilar Versavo in the UK [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Jul 16]. Available from: www.gabionline.net/biosimilars/news/dr-reddy-s-launches-bevacizumab-biosimilar-versavo-in-the-uk
5. GaBI Online - Generics and Biosimilars Initiative. Formycon launches biosimilar ranibizumab Ravegza in Saudi, Gedeon Richter invests [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Jul 16]. Available from: www.gabionline.net/pharma-news/formycon-launches-biosimilar-ranibizumab-ravegza-in-saudi-gedeon-richter-invests
6. GaBI Online - Generics and Biosimilars Initiative. Marvel withdraws biosimilar insulin applications [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Jul 4]. Available from: www.gabionline.net/Biosimilars/News/Marvel-withdraws-biosimilar-insulin-applications

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: EMA

Comments (2)

Post your comment

Posted 07/01/2022 by Anthika U, GaBI Online Editorial Office

Response to ‘Thorinane MA’ of Biosimilars approved in Europe

Dear Alexis Vaujany,
Thank you for your valuable comment received on 20/9/2021. We have updated the article tables of ‘Biosimilars approved in Europe’ with the correct information.
We very much appreciate your kind feedback. Thank you for your interest in GaBI, and please continue with your valuable comments to GaBI Online.
Best Regards, Anthika

Posted 20/09/2021 by Alexis Vaujany

Comment on updates

It seems that Thorinane's MA was withdrawn in 2019 because it has not been marketed in the European Union in the three years following the granting of the authorisation.

Generics and biosimilars Initiative

News

Research

General

News

Research

General